6 / 16
Page 32
Volume 5
Journal of Current Research: Cardiology
Heart Congress 2018
November 21-22, 2018
2
nd
Global Heart Congress
November 21-22, 2018 Osaka, Japan
FMTVDM©
℗
: A quantum leap forward for the fields of nuclear cardiology and nuclear medicine
Richard M Fleming
1
, Matthew R Fleming
1
and Andrew McKusick
1
and Tapan Chaudhuri
2
Omnific Imaging, USA
Eastern Virginia Medical School, USA
Background:
The foundational work of nuclear cardiology and nuclear medicine began with Blumgarts 1925 study of circulation
time. The method was actually quantitative yielding measurements of isotope over time. Unfortunately, the field of nuclear medicine
and later nuclear cardiology would yield to an approach of qualitative image interpretation resulting in problems with sensitivity and
specificity as do all qualitative methods, resulting in a 35% error rate, matching the limitations of anatomic assessment of disease,
including but not limited to coronary angiography, mammography, CT/MRI, etc.
Method:
300 men and women between ages 21 and 85 years of age were studied in five centers across the US, using a quantitative
and enhanced method (FMTVDM©
℗
) designed to measure isotope (Sestamibi and Myoview) redistribution to define wash-in,
washout and normal redistribution.
Result:
Results were compared to Quantitative CoronaryAngiography (QCA). Using FMTVD redistribution measurements, percent
Diameter Stenosis (%DS) was then calculated and the calculated %DS used to calculate a quantified/Fleming coronary flow
reserve© then used to calculate coronary artery narrowing (%DS) and QCFR/FCFR using the proprietary patent equations. The
resulting strong relationship for the coefficient of determination was 0.87582 (p<0.0001).
Conclusion:
Qualitative comparisons of nuclear imaging produces a diagnostic error rate of 35% comparable with angiographic
errors in reader interpretation and the inability to satisfactorily unmask underlying Vulnerable Inflammatory Plaques (VIPs)
responsible for roughly 85% of all myocardial infarctions. FMTVDM©
℗
provides the first ever quantified and enhanced method
for measuring Coronary Artery Disease (CAD) beginning with the measurement of isotope redistribution and ending with the
calculation of QCFR/FCFR© using the patented proprietary equations. This patented method is applicable to any device capable
of measuring isotope activity over time including but not limited to hand-held probes, planar, SPECT (Single-Photon Emission
Computed Tomography) and PET (Positron Emission Tomography). This provides the first quantitative and evolutionary change for
the fields of nuclear medicine and nuclear cardiology since its inception in 1925, (QCFR/FCFR) using proprietary equations. The
result was then compared with the QCA derived measurements using best fit regression analysis.
Results:
FMTVDM©
℗
measurements of Sestamibi and Myoview redistribution produced a parabolic relationship (p<0.01) and
showed that both technetium 99-m isotopes redistribute beginning at 5-minutes post isotope infusion compared with the 60-minute
distribution of isotope. Failure to correctly identify this timing of isotope redistribution had resulted in prior erroneous assumptions
that Sestamibi and Myoview did not redistribute.
rmfmd7@hotmail.comCurr Res Cardiol 2018, Volume 5
DOI: 10.4172/2368-0512-C1-003